The Manufacturers Life Insurance Company acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 44,327 shares of the company’s stock, valued at approximately $1,416,000. The Manufacturers Life Insurance Company owned approximately 0.07% of Tyra Biosciences as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Tyra Biosciences during the 2nd quarter worth about $96,841,000. Commodore Capital LP raised its position in shares of Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after acquiring an additional 2,150,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Tyra Biosciences by 32.5% during the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after purchasing an additional 955,147 shares during the last quarter. Farallon Capital Management LLC lifted its stake in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after purchasing an additional 923,000 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Tyra Biosciences in the first quarter valued at approximately $24,222,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Tyra Biosciences Trading Down 1.1%
NASDAQ TYRA opened at $24.86 on Friday. The business’s 50 day moving average is $29.09 and its two-hundred day moving average is $32.05. Tyra Biosciences, Inc. has a 12-month low of $11.70 and a 12-month high of $40.65. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.36 and a beta of 0.73.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on TYRA shares. Bank of America boosted their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. JonesTrading started coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price for the company. Finally, Wolfe Research assumed coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tyra Biosciences has an average rating of “Moderate Buy” and a consensus target price of $48.22.
Check Out Our Latest Report on Tyra Biosciences
About Tyra Biosciences
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report).
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
